Expiration date: 02/2026

Composition and form of issue:

1 tablet, film coated, contains letrozole 2, 5 mg in a package of 30 PCs.

Pharmacological action:

Competitively binds to the aromatase subunit-heme of cytochrome P450, inhibits the enzyme and reduces the biosynthesis of estrogens in tissues (peripheral and tumor).

Clinical pharmacology:

It eliminates the stimulating estrogenic effects and creates prerequisites for the suppression of tumor growth. It does not cause disorders of steroidogenesis in the adrenal glands, the level of Androstenedione in plasma.

Indications:

Breast cancer (advanced forms) in postmenopausal women (natural or induced artificially), receiving previous therapy with antiestrogens.

Contraindications:

Hypersensitivity, endocrine status characteristic of the premenopausal period.

Use during pregnancy and breast-feeding:

Contraindicated in pregnancy. Lactoirute women should give up breastfeeding.

Side effect:

Headache, General weakness, nausea, peripheral edema, tides, hair thinning, rash (mild or moderate).

Dosage and administration:

Inside, 2, 5 mg once a day, daily. Treatment is continued until the disease progresses.

Precautionary measures:

The relationship between the expected effect and the risk of treatment in patients with CL creatinine less than 10 ml/min should be carefully weighed (no data on use, but given the low plasma protein binding, it can be assumed that letrozole is subject to hemodialysis). Caution is recommended when driving or operating potentially dangerous machinery.